Stockscreener 앱 받기
3.88
1.02%
-0.04
전일 마감가:
$3.92
열려 있는:
$4.0749
하루 거래량:
4,100
Relative Volume:
0.04
시가총액:
$4.04M
수익:
-
순이익/손실:
$-10.31M
주가수익비율:
-1.6647
EPS:
-2.3308
순현금흐름:
$-6.32M
1주 성능:
-6.84%
1개월 성능:
-15.71%
6개월 성능:
-17.46%
1년 성능:
-62.11%
1일 변동 폭
$3.88
$4.23
1주일 범위
$3.8176
$4.23
52주 변동 폭
$3.2888
$13.20
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Compare GLMD vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
3.88 | 4.75M | 0 | -10.31M | -6.32M | -2.3308 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-05-22 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | 개시 | Craig Hallum | Buy |
| 2020-01-30 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-12-02 | 개시 | Canaccord Genuity | Buy |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-08-02 | 재확인 | Maxim Group | Buy |
| 2018-07-13 | 개시 | Stifel | Buy |
| 2018-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-06-12 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2018-02-14 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-15 | 개시 | ROTH Capital | Buy |
| 2017-08-08 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 재확인 | Maxim Group | Buy |
| 2016-08-01 | 재확인 | Maxim Group | Buy |
| 2016-07-06 | 재개 | ROTH Capital | Buy |
| 2016-03-28 | 재개 | H.C. Wainwright | Buy |
| 2015-06-23 | 개시 | H.C. Wainwright | Buy |
| 2015-05-06 | 개시 | Sun Trust Rbsn Humphrey | Buy |
모두보기
Galmed Pharmaceuticals Ltd 주식(GLMD)의 최신 뉴스
Galmed Pharmaceuticals Ltd.: Financial Data Forecasts Estimates and Expectations | GLMD | IL0011313900 - marketscreener.com
Galmed completes colon tissue assessment study - grafa.com
Galmed completes feasibility study for colon tissue assessment tech By Investing.com - Investing.com Nigeria
Galmed’s Colospan Unit Reports Successful First-in-Human Study for New Colorectal Surgery Platform - TipRanks
Colospan completes successful study on new colo... - Pluang
Galmed completes feasibility study for colon tissue assessment tech - Investing.com
Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology - PR Newswire
Galmed Reports Aramchol–Xtandi Combo Boosts Prostate Cancer Cell Death in Pre-Clinical Study - TipRanks
Galmed reports pre-clinical data on Aramchol-enzalutamide combo - Investing.com
Galmed reports pre-clinical data on Aramchol-enzalutamide combo By Investing.com - Investing.com UK
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models - Yahoo Finance Singapore
Galmed Pharmaceuticals to Enact 1-for-8 Reverse Share Split Effective August 19, 2026 - TipRanks
Galmed Pharmaceuticals (GLMD) to implement 1-for-8 reverse share split in August 2026 - Stock Titan
Galmed Pharmaceuticals (GLMD) Slips 6.1% to $0.56 as Selling Pressure IntensifiesIchimoku Kumo Twist - Vinanet
Galmed Pharmaceuticals (GLMD) Holds at $0.60 as Micro-Cap Biotech Trades Between Key LevelsHigh Yield Stocks - Vinanet
Galmed Pharmaceuticals Ltd (GLMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Galmed Pharmaceuticals (GLMD) Rises 5.4% to $0.62, Approaching Key ResistanceOpening Range Breakout - vinanet.vn
GLMD Q1 2026 Earnings: Surprise Profit Beats Estimates as Shares Gain 5.4%Earnings Deceleration Risk - Vinanet
Galmed Pharmaceuticals Wins Nasdaq Extension to Regain $1 Bid Price Compliance - TipRanks
Galmed Pharmaceuticals (NASDAQ: GLMD) granted new deadline to meet $1 bid rule - Stock Titan
Galmed Pharmaceuticals Ltd. (GLMD) Q1 2026 Earnings: Surprise Profit Driven by Expense Management and Non-Operating GainsEarnings Power Value - dars.gov.et
GLMD Q2'26 Earnings: EPS estimate is (0.39) USD - TradingView
Galmed advances Parkinson’s drug formulation with higher CNS exposure - Investing.com
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market - PR Newswire
Galmed Pharmaceuticals Ltd (GLMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galmed Pharmaceuticals Ltd - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GLMD|Galmed Pharmaceuticals Ltd|Price:0.602|Chg%:-0.004 - TradingKey
GLMD|Galmed Pharmaceuticals Ltd|Price:0.523|Chg%:-0.008 - TradingKey
Galmed Pharmaceuticals (GLMD) Slides 5.4%: Testing Key Support After Bearish MoveSymmetrical Triangle - vinanet.vn
Galmed Pharmaceuticals Ltd. Revenue Breakdown – NASDAQ:GLMD - TradingView
Galmed Pharmaceuticals Sets August 26, 2026 Annual Meeting to Approve Governance and Structural Changes - The Globe and Mail
Galmed Pharmaceuticals (GLMD) sets 2026 AGM on name change and pay - Stock Titan
GLMD Q1 2026 Earnings: Stellar EPS Surprise Despite Revenue Absence and Stock DeclineMargin Compression Risk - vinanet.vn
Galmed unveils heart-targeted Aramchol in cardiac fibrosis push - Indian Pharma Post
Galmed Accelerates Heart Failure Innovation with Aramchol - t.co
Galmed develops heart-targeted formulation of Aramchol drug By Investing.com - Investing.com South Africa
Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD) - Yahoo Finance
Galmed develops heart-targeted formulation of Aramchol drug - Investing.com
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) tests heart-targeted Aramchol LNPs - Stock Titan
Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol - PR Newswire
Galmed Pharmaceuticals (GLMD) Slips 2.16% as Shares Test Key Support Near $0.47Pairs Trade - vinanet.vn
Galmed Pharmaceuticals (GLMD) Sheds 4.75% as Biotech Volatility Pressures Near SupportPrice Action Signals - dars.gov.et
Galmed Pharmaceuticals (GLMD) Holds Steady at $0.57: Consolidation Phase with Key Levels in FocusSkew Index - dars.gov.et
Galmed Pharmaceuticals Reports Wider Q1 2026 Loss Amid Higher R&D Spending - TipRanks
Galmed (NASDAQ: GLMD) posts Q1 loss and closes Colospan acquisition - Stock Titan
GLMD|Galmed Pharmaceuticals Ltd|Price:0.513|Chg%:-0.040 - TradingKey
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - AOL.com
Galmed Pharmaceuticals (GLMD) Plunges Nearly 12% as Stock Tests Key Support at $0.54Trading Ideas - dars.gov.et
Galmed Pharmaceuticals (GLMD) Slides 12% as Selling Pressure Intensifies Near Key SupportMarket Neutral Pair - dars.gov.et
Galmed Pharmaceuticals Ltd. (GLMD) Q4 2025 Earnings: EPS Miss Extends Losses as Pre‑Revenue Biotech Faces Pipeline UncertaintyAnalyst Coverage Count - dars.gov.et
Galmed Pharmaceuticals Ltd (GLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):